Sarepta price target raised to $226 from $195 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Sarepta to $226 from $195 and keeps an Outperform rating on the shares after its Q4 results. The analyst is citing greater clarity around no AdComm being needed for ‘9001, with the FDA expressing comfort around ‘9001’s clinical package, and the company also addressing all CMS’s initial questions, the analyst tells investors in a research note. The firm remains positive on Sarepta’s continued improving outlook for the key value-driving DMD gene therapy and "would be buyers" of the stock on strength.